Vivozon Pharmaceutical Co., Ltd.
Financials
Valuation Metrics
Vivozon Pharmaceutical Co., Ltd.'s Market Cap is ₩1764B. At end of 2025 it was ₩2336B. Ranked #923 of 2,421 in KR market (top 38%), #442 of 1,640 on KOSDAQ (top 27%), #102 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 44%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 176.39B KRW | KR#923/2,421 Sec#102/231 |
| Revenue | 50.34B KRW | KR#1,791/2,421 Sec#122/231 |
| Net Income | -32.83B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 163.53B KRW | KR#1,444/2,421 Sec#111/231 |
| Net Assets | 95.30B KRW | KR#1,452/2,421 Sec#117/231 |
| Employees | 394 | KR#620/2,421 Sec#53/231 |
| Value | ||
| P/B | 1.85x | KR#1,893/2,421 Sec#139/231 |
| P/S | 3.50x | KR#2,048/2,421 Sec#130/231 |
| FCF Yield | -4.69% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -34.44% | KR#2,216/2,421 Sec#186/231 |
| ROA | -20.07% | KR#2,242/2,421 Sec#175/231 |
| Op. Margin | -37.52% | KR#2,202/2,421 Sec#156/231 |
| Revenue Growth | -39.54% | KR#2,261/2,421 Sec#200/231 |
| Financial Health | ||
| Debt Ratio | 71.59% | KR#1,242/2,421 Sec#150/231 |
| Total Debt | 32.20B KRW | KR#1,190/2,421 Sec#87/231 |
| FCF | -8.28B KRW | KR#1,652/2,421 Sec#136/231 |
| Cash | 8.72B KRW | KR#1,769/2,421 Sec#157/231 |
| Current Ratio | 0.66x | KR#2,062/2,421 Sec#196/231 |
| Performance | ||
| 1Y Return | -57.54% | KR#2,173/2,421 Sec#204/231 |
| 1M Return | -12.50% | KR#2,179/2,421 Sec#181/231 |
| From 52W High | -62.63% | KR#1,953/2,421 Sec#157/231 |
| 1Y MDD | -71.83% | KR#2,061/2,421 Sec#178/231 |
| Trading | ||
| Volume | 143,128 shares | KR#614/2,421 Sec#51/231 |
| Trading Value | 418.4M KRW | KR#996/2,421 Sec#100/231 |
| Foreign Own. | 1.43% | KR#1,852/2,421 Sec#183/231 |
| Per Share | ||
| EPS | -541 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,570 KRW | KR#2,178/2,421 Sec#188/231 |
Company Info
VIVAZON Pharm, established in 2002 and listed on KOSDAQ in 2005, is a finished pharmaceutical product manufacturing and sales company. It possesses over 190 items, including cardiovascular drugs, dermatological external preparations, and antipyretic analgesics and anti-inflammatory drugs, engaging in ETC, OTC, CMO, OEM businesses, and overseas exports. The company's pharmaceutical research institute focuses on developing generics, combination drugs, formulation changes, and differentiated products using controlled-release technology. VIVAZON Pharm is headquartered in Hwaseong-si, Gyeonggi-do.